Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma Meeting Abstract

  

Authors:	Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Hancock, H.; Davey, T.; Sohail, S.; Santarosa, A.; Pomerantz, L.; Jarjies, C.; Galasso, N.; Neuman, R.; Kumar, A.; Lahoud, O. B.; Batlevi, C. L.; Hamlin, P. A.; Straus, D. J.; Rodriguez-Rivera, I.; Owens, C.; Caron, P.; Intlekofer, A. M.; Hamilton, A.; Horwitz, S. M.; Falchi, L.; Joffe, E.; Palomba, M. L.; Noy, A.; Matasar, M. J.; Pongas, G.; Vardhana, S.; von Keudell, G. R.; Yahalom, J.; Zelenetz, A. D.; Moskowitz, C. H.
Abstract Title:	Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
Meeting Title:	62nd Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	136
Issue:	Suppl. 1
Meeting Dates:	2020 Dec 5-8
Meeting Location:	Virtual
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2020-11-05
Language:	English
ACCESSION:	WOS:000607205605159
DOI:	10.1182/blood-2020-138434
PROVIDER:	wos
Notes:	Meeting Abstract: 17 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/197818